Epidemiological studies have reported an increased risk of Parkinson’s disease (PD) development in amphetamine-type stimulant users during their lifetime (Garwood et al., 2006; Rumpf et al., 2017). Protein inclusions mainly composed of misfolded and aggregated α-synuclein are the pathological hallmark of PD and other disorders known as synucleinopathies.